Current Edition

Modelling and Simulation is Key to Modern Drug Development

The FDA has been promoting innovative and disruptive approaches towards modernizing drug development and clinical trials, which the industry has been slow to adopt. These methods, which include the use of predictive modelling and simulation (model-informed drug development, or MIDD), facilitate efficiency and cost-effectiveness in translating cutting-edge science into safe and efficacious treatments. Ellen Leinfuss, Certara, further examines the benefits of MIDD and concludes with how we must move forward with modern drug development.